BR112021017147A2 - Proteínas de domínio ccn recombinantes e proteínas de fusão - Google Patents
Proteínas de domínio ccn recombinantes e proteínas de fusãoInfo
- Publication number
- BR112021017147A2 BR112021017147A2 BR112021017147A BR112021017147A BR112021017147A2 BR 112021017147 A2 BR112021017147 A2 BR 112021017147A2 BR 112021017147 A BR112021017147 A BR 112021017147A BR 112021017147 A BR112021017147 A BR 112021017147A BR 112021017147 A2 BR112021017147 A2 BR 112021017147A2
- Authority
- BR
- Brazil
- Prior art keywords
- proteins
- recombinant
- ccn
- fusion
- fusion proteins
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000006998 CCN Intercellular Signaling Proteins Human genes 0.000 abstract 2
- 108010072756 CCN Intercellular Signaling Proteins Proteins 0.000 abstract 2
- 102000002938 Thrombospondin Human genes 0.000 abstract 2
- 108060008245 Thrombospondin Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
proteínas de domínio ccn recombinantes e proteínas de fusão. a presente invenção refere-se a proteínas recombinantes que possuem uma sequência de aminoácidos correspondente ou relacionada ao domínio de homologia de repetição de trombospondina tipo 1 de um membro das proteínas da família ccn e ao seu uso. além disso, a presente invenção refere-se a proteínas de fusão compreendendo uma sequência de aminoácidos correspondente ou relacionada ao domínio de homologia de repetição de trombospondina tipo 1 de um membro das proteínas da família ccn combinadas com um parceiro de fusão e, opcionalmente, uma região ligante. além disso, são descritos neste documento novos fragmentos fc resistentes à protease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19163970.7A EP3711772A1 (en) | 2019-03-20 | 2019-03-20 | Recombinant proteins and fusion proteins |
| PCT/EP2020/057773 WO2020188081A1 (en) | 2019-03-20 | 2020-03-20 | Recombinant ccn domain proteins and fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017147A2 true BR112021017147A2 (pt) | 2021-11-09 |
Family
ID=66102364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017147A BR112021017147A2 (pt) | 2019-03-20 | 2020-03-20 | Proteínas de domínio ccn recombinantes e proteínas de fusão |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220144903A1 (pt) |
| EP (2) | EP3711772A1 (pt) |
| JP (1) | JP2022525661A (pt) |
| KR (1) | KR20210142681A (pt) |
| CN (1) | CN113747912A (pt) |
| AU (1) | AU2020243073A1 (pt) |
| BR (1) | BR112021017147A2 (pt) |
| CA (1) | CA3133740A1 (pt) |
| IL (1) | IL285930A (pt) |
| MX (1) | MX2021011407A (pt) |
| SG (1) | SG11202109738QA (pt) |
| WO (1) | WO2020188081A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999047556A2 (en) * | 1998-03-19 | 1999-09-23 | Trustees Of Tufts College | Novel heparin-induced ccn-like molecules and uses therefor |
| FR2858234B1 (fr) * | 2003-08-01 | 2007-09-14 | Centre Nat Rech Scient | Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers |
| DE602006021534D1 (de) * | 2005-01-10 | 2011-06-09 | Univ Rosalind Franklin Medicine & Science | CCN3 Proteine zur Behandlung und Diagnose von Nierenerkrankungen |
| CN104277117A (zh) * | 2005-01-24 | 2015-01-14 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的Fc融合构建体及其治疗用途 |
| WO2007033215A2 (en) * | 2005-09-12 | 2007-03-22 | The Johns Hopkins University | Compositions having antiangiogenic activity and uses thereof |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US20080207489A1 (en) | 2007-02-21 | 2008-08-28 | John Castellot | Use of CCN5 for treatment of smooth muscle proliferation disorders |
| DK3061817T3 (en) * | 2009-04-30 | 2019-03-04 | Kao Corp | Alkaline protease variants |
| AU2010292329B2 (en) * | 2009-09-09 | 2016-07-21 | Pharmain Corporation | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same |
| KR101187814B1 (ko) | 2010-03-22 | 2012-10-08 | 광주과학기술원 | 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법 |
| ES2561437T3 (es) * | 2010-04-02 | 2016-02-26 | Rosalind Franklin University Of Medicine And Science | Péptidos de CCN3 y análogos de los mismos para uso terapéutico |
| US9114112B2 (en) * | 2010-04-02 | 2015-08-25 | Rosalind Franklin University Of Medicine And Science | CCN3 and CCN3 peptides and analogs thereof for therapeutic uses |
| AU2011349719B2 (en) | 2010-12-23 | 2016-09-15 | Janssen Biotech, Inc. | Active protease-resistant antibody Fc mutants |
| GB201316592D0 (en) | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| CN105396136B (zh) * | 2015-11-23 | 2018-10-30 | 上海交通大学医学院附属第九人民医院 | CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用 |
| UA125378C2 (uk) | 2016-03-14 | 2022-03-02 | Універшітетет І Осло | МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn |
| US20180127478A1 (en) | 2016-09-16 | 2018-05-10 | Wei-Chiang Shen | SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY |
| KR20180099537A (ko) * | 2017-02-28 | 2018-09-05 | 주식회사 파이안바이오테크놀로지 | 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제 |
-
2019
- 2019-03-20 EP EP19163970.7A patent/EP3711772A1/en not_active Withdrawn
-
2020
- 2020-03-20 CA CA3133740A patent/CA3133740A1/en active Pending
- 2020-03-20 EP EP20711209.5A patent/EP3941507A1/en active Pending
- 2020-03-20 CN CN202080023396.5A patent/CN113747912A/zh active Pending
- 2020-03-20 US US17/440,576 patent/US20220144903A1/en active Pending
- 2020-03-20 SG SG11202109738Q patent/SG11202109738QA/en unknown
- 2020-03-20 MX MX2021011407A patent/MX2021011407A/es unknown
- 2020-03-20 BR BR112021017147A patent/BR112021017147A2/pt unknown
- 2020-03-20 WO PCT/EP2020/057773 patent/WO2020188081A1/en active Application Filing
- 2020-03-20 KR KR1020217033515A patent/KR20210142681A/ko active Search and Examination
- 2020-03-20 AU AU2020243073A patent/AU2020243073A1/en active Pending
- 2020-03-20 JP JP2021556442A patent/JP2022525661A/ja active Pending
-
2021
- 2021-08-29 IL IL285930A patent/IL285930A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3133740A1 (en) | 2020-09-24 |
| AU2020243073A1 (en) | 2021-11-11 |
| EP3941507A1 (en) | 2022-01-26 |
| WO2020188081A1 (en) | 2020-09-24 |
| US20220144903A1 (en) | 2022-05-12 |
| JP2022525661A (ja) | 2022-05-18 |
| MX2021011407A (es) | 2022-01-24 |
| EP3711772A1 (en) | 2020-09-23 |
| SG11202109738QA (en) | 2021-10-28 |
| CN113747912A (zh) | 2021-12-03 |
| IL285930A (en) | 2021-10-31 |
| KR20210142681A (ko) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| BR112014017165A2 (pt) | polipeptídeos de fator quimérico viii e seus usos | |
| ES2676499T3 (es) | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones | |
| BR112016015512A2 (pt) | proteínas quiméricas de fator viii e suas utilizações | |
| BR112018075363A2 (pt) | neurotoxinas botulínicas manipuladas | |
| BR112016016411A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS | |
| BR122020006918B8 (pt) | Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
| CR20180509A (es) | Contorsbody - un ligante de diana monocatenario | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| BR112012019881A2 (pt) | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
| AR103714A1 (es) | Proteínas específicas para pioverdina y pioquelina | |
| BR112015014727B8 (pt) | Composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| BR112013013548B8 (pt) | Proteína de fusão anticancerígena | |
| Fae et al. | PDIA3, HSPA5 and vimentin, proteins identified by 2-DE in the valvular tissue, are the target antigens of peripheral and heart infiltrating T cells from chronic rheumatic heart disease patients | |
| CO2022016595A2 (es) | Nuevas proteinas de unión a repeticiones de anquirina y sus usos | |
| BR112018003594A2 (pt) | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados | |
| EA202190240A1 (ru) | Варианты рекомбинантного белка | |
| BR112021017147A2 (pt) | Proteínas de domínio ccn recombinantes e proteínas de fusão | |
| BR112018073280A2 (pt) | cd200 mutantes e seus usos | |
| BR112022017032A2 (pt) | Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas. | |
| BR112014008025A2 (pt) | chamarizes de notch1 humano | |
| BR112018012055A2 (pt) | substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico |